fbpx
Blog thumbnail

The Clinical Endocannabinoid Deficiency Science

Blog thumbnail in

Technological advancements have helped people discover treatments for various debilitating conditions. But there are still some illnesses that have no known causes and treatments yet. A study done on the ECS or endocannabinoid system has given experts a new perspective on illnesses such as fibromyalgia, migraine, and IBS or irritable bowel syndrome. Read on to find out more about these studies. 

Clinical Endocannabinoid Deficiency

In order for the ECS to efficiently function, the body should be able to produce the endocannabinoids and this can be in the form of naturally-occurring chemicals similar to cannabis like the anandamide and 2-Arachidonoylglycerol. It was found through various studies that certain people have a much lower level of endocannabinoids compared to the others, which is what triggers the various health complications.

There have been increasing clinical researches that link anxiety with reduced anandamide levels while major depression could happen because of reduced 2-AG levels. Once the body is unable to produce endocannabinoids in the required concentrations, a chemical imbalance will take place and this is what leads to the illnesses.

Fibromyalgia and Clinical Endocannabinoid Deficiency

Medical researchers have been unable to figure out the real reason behind fibromyalgia. Patients suffering from this condition need to deal with a wide array of debilitating symptoms that could negatively affect their quality of life. Furthermore, a big percentage of fibromyalgia sufferers are suffering from mental conditions, such as anxiety. In one study, it was found that CBD could help treat chronic endocannabinoid deficiency anxiety.

In addition, several of the fibromyalgia symptoms could be a sign of ECS dysregulation. For example, inflammatory conditions happen as a result of some issues in the immune systems response and modulated by the ECS and the CB2 receptor specifically. It’s also been found that the serotonin levels of patients suffering from endocannabinoid deficiency fibromyalgia could be affected and this is something noteworthy knowing that CBD is a substance that’s considered an agonist of 5-HT1A receptor, a subtype of the serotonin receptor.

Migraines and Clinical Endocannabinoid Deficiency

Millions of Americans suffer from migraines which also comes with other debilitating symptoms such as nausea, dizziness, tingling, and face numbness. Research shows that people suffering from migraines have significant differences of anandamide levels on their cerebrospinal fluid, which is located in the spinal cord and the brain.

In a 2017 research, experts found that changes in the endocannabinoid system could help alleviate symptoms of migraines, which is one of the causes of endocannabinoid deficiency. Results show that the anandamide, which is a key neurotransmitter in the endocannabinoid system, can increase the effectiveness of 5-HT1A receptor and inhibit the 5-HT2A receptor. This is an effective preventative treatment for migraines while treating acute migraines as well. Furthermore, results also showed that most of the cannabinoids exhibit dopamine-blocking effects and contain anti-inflammatory properties. Thus, when it comes to knowing how to treat endocannabinoid deficiency like migraines, CBD is definitely the answer.

Shopping cart

0

No products in the cart.

Hit Enter to search or Esc key to close